About 1.1 million people are estimated to have age-related macular degeneration in West Germany. Anatomical aspects of the normal macula and physiological ageing processes in the retina will be discribed including alt...About 1.1 million people are estimated to have age-related macular degeneration in West Germany. Anatomical aspects of the normal macula and physiological ageing processes in the retina will be discribed including alterations in the choroid, in Bruch's membrane, the pigment epithelium and the sensory retina. Risk factors for the development of age-related macular degeneration are age per se, perhaps ethnologic characteristics, ocular characteristics, and perhaps environmental factors. The histopathology...展开更多
AIM: To evaluate the association of complement factor H(CFH) and microtubule-associated protein 1 light chain 3 beta(MAP1LC3B) gene polymorphisms with the risk of age-related macular degeneration(AMD) in a high-altitu...AIM: To evaluate the association of complement factor H(CFH) and microtubule-associated protein 1 light chain 3 beta(MAP1LC3B) gene polymorphisms with the risk of age-related macular degeneration(AMD) in a high-altitude population. METHODS: The study group consisted of 172 participants with symptoms of AMD who were examined and diagnosed between January 2019 and June 2020. The control group was composed of 120 healthy individuals. Each participant was required to provide two milliliters of peripheral blood for DNA extraction. Two single nucleotide polymorphisms(SNPs) of CFH(rs1061170 and rs800292) and two SNPs of MAP1LC3B(rs8044820 and rs9903) were genotyped. The genotypes and allele frequencies of the SNPs in the study and control groups were further compared using Chi-square and Fisher’s exact tests. RESULTS: In a high-altitude population, the nominally significant differences of rs800292 and rs9903’s genotype AG frequencies were observed in the AMD group(P=0.034 and 0.004, respectively). The frequencies of allele G of rs800292 and allele A of rs9903 were also significantly dif ferent in the AMD group compared to the control [(P=0.034, OR=0.70, 95%CI: 0.50-0.98) and(P=0.004, OR=1.60, 95%CI: 1.15-2.22), respectively]. No significant differences in the genotype distributions(P=0.16 and 0.40, respectively) and allele frequencies(P>0.05) of rs1061170 and rs8044820 were observed in the AMD group.CONCLUSION: Genotype AG of rs800292 may be a protective factor for AMD. Conversely, rs9903 seems to be a risk factor for AMD. Therefore, allele G of rs800292 may be a protective factor, and allele A of rs9903, a risk factor for AMD in Qinghai high-altitude population.展开更多
AIM: To investigate the serum level of the brain derived neurotrophic factor (BDNF) in age -related macular degeneration (AMD) and healthy control subjects. The disruption in the tight balance of neuroinflammatory and...AIM: To investigate the serum level of the brain derived neurotrophic factor (BDNF) in age -related macular degeneration (AMD) and healthy control subjects. The disruption in the tight balance of neuroinflammatory and neuroprotective processes in an immune -privileged site like retina is proposed to contribute to the pathogenesis of AMD. One of the main neuroprotective mediators in the central nervous system Is BDNF with its serum level notably affected in several neurodegenerative disorders. METHODS: Thirty-six patients'with AMD and 36 age-matched controls were enrolled in this study. The serum level of BDNF was measured using the enzyme -linked immunosorbent assay method. Results were analyzed to compare case and control values. Comparisons were also made between the BDNF level of wet- vsdry-AMD, and male vs female patients and controls. Analysis of variance (ANOVA) and Student's t-test were employed to analyze the data. RESULTS: The mean BDNF levels in AMD group were significantly higher than the control group. Furthermore, our analysis revealed greater BDNF values in all AMD subgroups compared to controls (P=0.004, 0.005, 0.001 and 0.02 for male wet-AMD, male dry-AMD, female wetAMD and female dry-AMD vscontrols, respectively). The BDNF level however did not vary between wet- and dryAMD patients (P=0.74). While within-group comparisons in males and females of AMD and control groups did not show any difference in BDNF (P=0.16, 0.64 and 0.85 for wet -AMD, dry -AMD and control groups, respectively), between -group data showed a higher mean BDNF in both male and female AMD subjects than their peer controls. CONCLUSION: This study demonstrated that the serum BDNF level is different in patients with AMD as compared to subjects without AMD. Future attempts should be done to unravel beneficial or deleterious effect of this neurotrophin in the pathogenesis of AMD.展开更多
目的:评价中药联合玻璃体腔内注射抗血管内皮生长因子(VEGF)与单纯抗VEGF药物治疗湿性年龄相关性黄斑变性(wAMD)的疗效。方法:检索中国知网、万方、维普、中国生物医学库CBM、Pubmed、Web of Science、Cochrane Library、Embase八大数据...目的:评价中药联合玻璃体腔内注射抗血管内皮生长因子(VEGF)与单纯抗VEGF药物治疗湿性年龄相关性黄斑变性(wAMD)的疗效。方法:检索中国知网、万方、维普、中国生物医学库CBM、Pubmed、Web of Science、Cochrane Library、Embase八大数据库,发表于建库以来至2022-04-20所有中英文文献。选取研究对象为wAMD患者,研究方法为比较中药联合抗VEGF药物与单纯抗VEGF药物治疗的临床随机对照实验研究。采用的结局指标为最佳矫正视力(BCVA),黄斑中心凹厚度(CMT)。采用传统Meta和网状Meta分析对数据进行统计。结果:在617项确定的研究中,39项纳入分析,涉及28种口服中药,2757名参与者。在提高BCVA方面,中药联合抗VEGF药物治疗优于单纯抗VEGF药物治疗(MD=0.07,95%CI:0.05~0.09)。生蒲黄汤(SPD)在治疗后1、2mo最佳,血府逐瘀胶囊(XZC)在治疗后3mo最佳。在降低CMT方面,中药联合治疗效果更好(MD=-25.32μm,95%CI:-30.06~-20.57)。当归明目汤(DMD)在治疗1mo后效果最好。补肾活血汤(BHD)在2mo时疗效最好。二陈二黄汤(EED)在3mo时疗效最好。结论:与单纯抗VEGF治疗相比,中药联合治疗可改善BCVA,降低CMT。然而,纳入的文献多为小样本、单中心、单盲随机对照试验,文献质量总体较低。展开更多
文摘About 1.1 million people are estimated to have age-related macular degeneration in West Germany. Anatomical aspects of the normal macula and physiological ageing processes in the retina will be discribed including alterations in the choroid, in Bruch's membrane, the pigment epithelium and the sensory retina. Risk factors for the development of age-related macular degeneration are age per se, perhaps ethnologic characteristics, ocular characteristics, and perhaps environmental factors. The histopathology...
文摘AIM: To evaluate the association of complement factor H(CFH) and microtubule-associated protein 1 light chain 3 beta(MAP1LC3B) gene polymorphisms with the risk of age-related macular degeneration(AMD) in a high-altitude population. METHODS: The study group consisted of 172 participants with symptoms of AMD who were examined and diagnosed between January 2019 and June 2020. The control group was composed of 120 healthy individuals. Each participant was required to provide two milliliters of peripheral blood for DNA extraction. Two single nucleotide polymorphisms(SNPs) of CFH(rs1061170 and rs800292) and two SNPs of MAP1LC3B(rs8044820 and rs9903) were genotyped. The genotypes and allele frequencies of the SNPs in the study and control groups were further compared using Chi-square and Fisher’s exact tests. RESULTS: In a high-altitude population, the nominally significant differences of rs800292 and rs9903’s genotype AG frequencies were observed in the AMD group(P=0.034 and 0.004, respectively). The frequencies of allele G of rs800292 and allele A of rs9903 were also significantly dif ferent in the AMD group compared to the control [(P=0.034, OR=0.70, 95%CI: 0.50-0.98) and(P=0.004, OR=1.60, 95%CI: 1.15-2.22), respectively]. No significant differences in the genotype distributions(P=0.16 and 0.40, respectively) and allele frequencies(P>0.05) of rs1061170 and rs8044820 were observed in the AMD group.CONCLUSION: Genotype AG of rs800292 may be a protective factor for AMD. Conversely, rs9903 seems to be a risk factor for AMD. Therefore, allele G of rs800292 may be a protective factor, and allele A of rs9903, a risk factor for AMD in Qinghai high-altitude population.
文摘AIM: To investigate the serum level of the brain derived neurotrophic factor (BDNF) in age -related macular degeneration (AMD) and healthy control subjects. The disruption in the tight balance of neuroinflammatory and neuroprotective processes in an immune -privileged site like retina is proposed to contribute to the pathogenesis of AMD. One of the main neuroprotective mediators in the central nervous system Is BDNF with its serum level notably affected in several neurodegenerative disorders. METHODS: Thirty-six patients'with AMD and 36 age-matched controls were enrolled in this study. The serum level of BDNF was measured using the enzyme -linked immunosorbent assay method. Results were analyzed to compare case and control values. Comparisons were also made between the BDNF level of wet- vsdry-AMD, and male vs female patients and controls. Analysis of variance (ANOVA) and Student's t-test were employed to analyze the data. RESULTS: The mean BDNF levels in AMD group were significantly higher than the control group. Furthermore, our analysis revealed greater BDNF values in all AMD subgroups compared to controls (P=0.004, 0.005, 0.001 and 0.02 for male wet-AMD, male dry-AMD, female wetAMD and female dry-AMD vscontrols, respectively). The BDNF level however did not vary between wet- and dryAMD patients (P=0.74). While within-group comparisons in males and females of AMD and control groups did not show any difference in BDNF (P=0.16, 0.64 and 0.85 for wet -AMD, dry -AMD and control groups, respectively), between -group data showed a higher mean BDNF in both male and female AMD subjects than their peer controls. CONCLUSION: This study demonstrated that the serum BDNF level is different in patients with AMD as compared to subjects without AMD. Future attempts should be done to unravel beneficial or deleterious effect of this neurotrophin in the pathogenesis of AMD.
文摘目的:评价中药联合玻璃体腔内注射抗血管内皮生长因子(VEGF)与单纯抗VEGF药物治疗湿性年龄相关性黄斑变性(wAMD)的疗效。方法:检索中国知网、万方、维普、中国生物医学库CBM、Pubmed、Web of Science、Cochrane Library、Embase八大数据库,发表于建库以来至2022-04-20所有中英文文献。选取研究对象为wAMD患者,研究方法为比较中药联合抗VEGF药物与单纯抗VEGF药物治疗的临床随机对照实验研究。采用的结局指标为最佳矫正视力(BCVA),黄斑中心凹厚度(CMT)。采用传统Meta和网状Meta分析对数据进行统计。结果:在617项确定的研究中,39项纳入分析,涉及28种口服中药,2757名参与者。在提高BCVA方面,中药联合抗VEGF药物治疗优于单纯抗VEGF药物治疗(MD=0.07,95%CI:0.05~0.09)。生蒲黄汤(SPD)在治疗后1、2mo最佳,血府逐瘀胶囊(XZC)在治疗后3mo最佳。在降低CMT方面,中药联合治疗效果更好(MD=-25.32μm,95%CI:-30.06~-20.57)。当归明目汤(DMD)在治疗1mo后效果最好。补肾活血汤(BHD)在2mo时疗效最好。二陈二黄汤(EED)在3mo时疗效最好。结论:与单纯抗VEGF治疗相比,中药联合治疗可改善BCVA,降低CMT。然而,纳入的文献多为小样本、单中心、单盲随机对照试验,文献质量总体较低。
